Delcath Systems, Inc. DCTH

DRUG PIPELINE
ANALYST RATINGS
INSIDER TRADES
DEVICE PIPELINE
NEWS
$3.12
-0.04 -1.27%
PREVIOUS CLOSE
3.16
OPEN
3.27
52 WEEK LOW
2.34
52 WEEK HIGH
7.99
MARKET CAP
$48M
OPTIONS
Y
SHARES
15M
FLOAT
8.1M
ENTERPRISE VALUE
$33M
VOLUME
840K
AV. DAILY VOLUME
178K

DCTH will go up to 17$

INSIDER NAME INSIDER POSITION FILING DATE BUY/SELL STOCK/OPTION SHARES SHARES CHANGE PRICE COST FINAL SHARE
Sandra Pennell 11/06/2023 ET Buy Option 100K 0% $0.00 $0.00 100K
PHD ROGER STOLL Director 11/06/2023 ET Buy Option 19.68K 0% $0.00 $0.00 19.68K
David L Hoffman 11/06/2023 ET Buy Option 59.81K 0% $0.00 $0.00 59.81K
Gerard Michel Director 11/06/2023 ET Buy Option 168.89K 0% $0.00 $0.00 168.89K
ELIZABETH CZEREPAK Director 11/06/2023 ET Buy Option 19.68K 0% $0.00 $0.00 19.68K
Johnny John 11/06/2023 ET Buy Option 59.81K 0% $0.00 $0.00 59.81K
Richard John Sylvester Director 11/06/2023 ET Buy Option 19.68K 0% $0.00 $0.00 19.68K
John Purpura Chief Operating Officer 11/06/2023 ET Buy Option 59.81K 0% $0.00 $0.00 59.81K
Kevin Muir 11/06/2023 ET Buy Option 59.81K 0% $0.00 $0.00 59.81K
STEVEN SALAMON Director 11/06/2023 ET Buy Option 19.68K 0% $0.00 $0.00 19.68K
Gil Aharon Director 11/06/2023 ET Buy Option 19.68K 0% $0.00 $0.00 19.68K
ROSALIND ADVISORS, INC. Director 17/04/2023 ET Buy Option 538.83K 297.47% $5.63 $3,033,601.64 719.97K

RATINGSINSIDER TRADESDEVICE PIPELINENEWS$3.12-0.04  -1.27%PREVIOUS CLOSE3.16OPEN3.2752 WEEK LOW2.3452 WEEK HIGH7.99MARKET CAP$48MOPTIONSYSHARES15MFLOAT8.1MENTERPRISE VALUE$33MVOLUME840KAV. DAILY VOLUME178KCOMPANY CASH DATABASELIVE CASH EST$9.64MCASH BURN-$3.23MNO. MTHS CASH2.98INSIDERS %2TOTAL DEBT TO EQUITYN/ABIOTECH EARNINGS CALENDAREARNINGS DATE09/08/2023 ETEPS EST.-0.600EPS PRIOR.-1.180EPS-0.580REV GUIDANCE$797.00KDCTH Stock PriceDCTH Drug PipelineDRUGSTAGECATALYST DATEIpilimumab plus nivolumab - (CHOPIN)Uveal melanomaPhase 1bPhase 1b initial results of the trial in seven patients resulted in 85.7% Best Overall Response and 100% Disease Control Rate. Median progression free survival currently is 22.4 months with all patients still alive as of last follow-up, noted June 6, 2022. Phase 1b updated results in seven patients with advanced uveal melanoma treated with CHEMOSAT and ipilimumab plus nivolumab show a Median PFS of 29.1 months, 7/7 patients treated still alive as of last follow-up, noted January 17, 2023.Melphalan/HDS - (ALIGN)Intrahepatic CholangiocarcinomaPhase 3Phase 3 trial has been initiated.HEPZATO (Melphalan/HDS) - (FOCUS)Liver-dominant ocular melanomaApprovedFDA Approved on August 14, 2023.BioPharmCatalyst's Dashboard for In‑Depth Trial AnalysisExploreDCTH Analyst RatingsANALYSTACTIONRATING NOWPT PRIORPT NOWLAST UPDATEDHC Wainwright & Co.ReiteratesBuyN/A$175/24/2023HC Wainwright & Co.MaintainsBuy$19$173/28/2023HC Wainwright & Co.MaintainsBuy$25$198/10

RATINGSINSIDER TRADESDEVICE PIPELINENEWS$3.12-0.04  -1.27%PREVIOUS CLOSE3.16OPEN3.2752 WEEK LOW2.3452 WEEK HIGH7.99MARKET CAP$48MOPTIONSYSHARES15MFLOAT8.1MENTERPRISE VALUE$33MVOLUME840KAV. DAILY VOLUME178KCOMPANY CASH DATABASELIVE CASH EST$9.64MCASH BURN-$3.23MNO. MTHS CASH2.98INSIDERS %2TOTAL DEBT TO EQUITYN/ABIOTECH EARNINGS CALENDAREARNINGS DATE09/08/2023 ETEPS EST.-0.600EPS PRIOR.-1.180EPS-0.580REV GUIDANCE$797.00KDCTH Stock PriceDCTH Drug PipelineDRUGSTAGECATALYST DATEIpilimumab plus nivolumab - (CHOPIN)Uveal melanomaPhase 1bPhase 1b initial results of the trial in seven patients resulted in 85.7% Best Overall Response and 100% Disease Control Rate. Median progression free survival currently is 22.4 months with all patients still alive as of last follow-up, noted June 6, 2022. Phase 1b updated results in seven patients with advanced uveal melanoma treated with CHEMOSAT and ipilimumab plus nivolumab show a Median PFS of 29.1 months, 7/7 patients treated still alive as of last follow-up, noted January 17, 2023.Melphalan/HDS - (ALIGN)Intrahepatic CholangiocarcinomaPhase 3Phase 3 trial has been initiated.HEPZATO (Melphalan/HDS) - (FOCUS)Liver-dominant ocular melanomaApprovedFDA Approved on August 14, 2023.BioPharmCatalyst's Dashboard for In‑Depth Trial AnalysisExploreDCTH Analyst RatingsANALYSTACTIONRATING NOWPT PRIORPT NOWLAST UPDATEDHC Wainwright & Co.ReiteratesBuyN/A$175/24/2023HC Wainwright & Co.MaintainsBuy$19$173/28/2023HC Wainwright & Co.MaintainsBuy$25$198/10

https://microcapdaily.com/the-inside-scoop-on-inspyr-therapeutics-inc-otcmkts-nspx/125607/